Jan. 14 at 9:49 PM
$EOLS
What a clown show. I have been an investor since 2018….thru FDA review and approval, the Medytox/Allergan USITC fiasco, and the pandemic, etc
The 2026 guidance provided last week is shameful. If you look at the investor presentation on the eols website dated 1/9, it shows tox market now only expected to grow from2.6b in 2025 to 3.2b in 2028, a CAGR of 7%. Their guidance for the tox portion of revenue in 3026 is 8% using midpoints of ranges and backing out midpoint of filler range.
Executive mgmt getting paid a huge salary and big stock grants for basically growing at market. All while spending sg&a like drunken sailors. They can’t possibly really expect to perform this poorly. If so, get new leadership or a new BOD that will hold them accountable for better than average performance.
Shameful.
